Read a bit more about the Stimuvax trial and its measurement targets.
Sounds like it was never going to meet the required Standards as set by the FDA. i.e. it appears that they may not have set up the trial properly.
I beleive that there is a lot more rigour around the trial and end point targets put in place by Prima.
http://seekingalpha.com/article/281421-oncothyreon-phase-iii-unlikely-to-show-survival-benefit
LC
bad news for onty - stimuvax fails p3 trial, page-4
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.005(1.59%) |
Mkt cap ! $469.0M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 31.0¢ | $1.599M | 5.009M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 65758 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 6777 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |